Literature DB >> 23015464

Small-vessel disease in patients with Parkinson's disease: a clinicopathological study.

Raymond S Schwartz1, Glenda M Halliday, Dennis J Cordato, Jillian J Kril.   

Abstract

Few studies have examined the relationship between cerebrovascular disease, vascular risk factors, and Parkinson's disease (PD), although 1 study found small-vessel disease (SVD) to be the main subtype of cerebrovascular disease. In this study we compared the extent and topography of SVD and assessed associated vascular risk factors in autopsy-proven PD cases and community-dwelling controls. Seventy-seven PD and 32 control brains from the Sydney Brain Bank were assessed microscopically by a single examiner blinded to the diagnosis. SVD was assessed by grading perivascular pallor, gliosis, hyaline thickening, and enlargement of perivascular spaces in the white matter underlying the superior frontal and primary motor cortices, basal ganglia, and white matter tracts. A history of vascular risk factors (hypertension, heart disease, diabetes, and cigarette smoking) was obtained. Groups were compared using stepwise multiple regression analysis. There was significantly greater frontal pallor (P = .004) and widening of perivascular spaces in the globus pallidus interna (P = .007) in controls compared with PD. Hyaline thickening and widening of perivascular spaces in the frontal white matter, hyaline thickening in the motor white matter, and widening of perivascular spaces in the caudate nucleus were more common in the control group, but did not reach significance. The prevalence of vascular risk factors and SVD pathology was significantly lower in autopsy-proven PD compared with controls (P = .03) living in the same community. The results of this study support the need for further research in this area.
Copyright © 2012 Movement Disorder Society.

Entities:  

Mesh:

Year:  2012        PMID: 23015464     DOI: 10.1002/mds.25112

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  14 in total

Review 1.  The neurobiological basis of cognitive impairment in Parkinson's disease.

Authors:  Glenda M Halliday; James B Leverenz; Jay S Schneider; Charles H Adler
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

Review 2.  Catechol-O-methyltransferase inhibitors in Parkinson's disease.

Authors:  Thomas Müller
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

3.  Development of Parkinson Disease and Its Relationship with Incidentally Discovered White Matter Disease and Covert Brain Infarction in a Real-World Cohort.

Authors:  David M Kent; Lester Y Leung; Eric J Puttock; Andy Y Wang; Patrick H Luetmer; David F Kallmes; Jason Nelson; Sunyang Fu; Chengyi Zheng; Ellen M Vickery; Hongfang Liu; Alastair J Noyce; Wansu Chen
Journal:  Ann Neurol       Date:  2022-08-17       Impact factor: 11.274

4.  Cognitive Performance is Associated with Altered Cerebral Hemodynamics Assessed by Transcranial Ultrasound in Parkinson's Disease.

Authors:  Yi-Lun Ge; Si-Yi Gong; Pu-Zhi Wang; Jia-Hui Yan; Wen Li; Jin-Ru Zhang; Hong Jin; Sheng Zhuang; Lei Hu; Chang-Wei Ding; Ya-Ping Yang; Fen Wang; Dan Li; Jing Chen; Cheng-Jie Mao; Ying-Chun Zhang; Kai Li; Chun-Feng Liu
Journal:  Neuropsychiatr Dis Treat       Date:  2022-07-12       Impact factor: 2.989

5.  Cerebral small vessel disease and incident parkinsonism: The RUN DMC study.

Authors:  Helena M van der Holst; Inge W M van Uden; Anil M Tuladhar; Karlijn F de Laat; Anouk G W van Norden; David G Norris; Ewoud J van Dijk; Rianne A J Esselink; Bram Platel; Frank-Erik de Leeuw
Journal:  Neurology       Date:  2015-10-07       Impact factor: 9.910

6.  Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre.

Authors:  Jon B Toledo; Steven E Arnold; Kevin Raible; Johannes Brettschneider; Sharon X Xie; Murray Grossman; Sarah E Monsell; Walter A Kukull; John Q Trojanowski
Journal:  Brain       Date:  2013-07-10       Impact factor: 13.501

7.  Reduced macular thickness and macular vessel density in early-treated adult patients with PKU.

Authors:  Csilla Serfozo; Andras Gellert Barta; Endre Horvath; Csaba Sumanszki; Bela Csakany; Miklos Resch; Zoltan Zsolt Nagy; Peter Reismann
Journal:  Mol Genet Metab Rep       Date:  2021-05-05

8.  Eryptosis as a marker of Parkinson's disease.

Authors:  Etheresia Pretorius; Albe C Swanepoel; Antoinette V Buys; Natasha Vermeulen; Wiebren Duim; Douglas B Kell
Journal:  Aging (Albany NY)       Date:  2014-10       Impact factor: 5.682

9.  Evaluation of Retinal Vessel Morphology in Patients with Parkinson's Disease Using Optical Coherence Tomography.

Authors:  Robert Kromer; Carsten Buhmann; Ute Hidding; Matthias Keserü; Diana Keserü; Andrea Hassenstein; Birthe Stemplewitz
Journal:  PLoS One       Date:  2016-08-15       Impact factor: 3.240

10.  Comparison of peripapillary choroidal thickness between healthy subjects and patients with Parkinson's disease.

Authors:  Elena Garcia-Martin; Luis E Pablo; Maria P Bambo; Raquel Alarcia; Vicente Polo; Jose M Larrosa; Elisa Vilades; Beatriz Cameo; Elvira Orduna; Teresa Ramirez; Maria Satue
Journal:  PLoS One       Date:  2017-05-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.